Skip to main content

Table 1 Demographics of study population

From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

No. patients 12
Age at transplant, yr ± SD (range) 52.88 ± 4.70 (44–60)
Time posttransplant, yr ± SD (range) 7.70 ± 6.31 (1–21)
Age at study, yr ± SD (range) 60.58 ± 7.10 (48–70)
Gender (M:F) 10:2
Immunosuppression at study  
  Tacrolimus 7/12
  Cyclosporine 2/12
  mTor inhibitors 3/12
ALT, U/L ± SD 131.4 ± 117.2
AST, U/L ± SD 85.0 ± 52.6
Total bilirubin, mg/dl ± SD 1.79 ± 2.31
HCV genotype (1/2/3; %) 75/8/17
IL28B genotype (CC/CT/TT; %) 25/50/25
HCV-RNA (log 10 IU/ml; mean ± SD) 6.38 ± 0.58